广州安必平医药科技股份有限公司 独立董事提名人声明与承诺 提名人广州安必平医药科技股份有限公司董事会，现提名吴翔为 广州安必平医药科技股份有限公司第四届董事会独立董事候选人，并 已充分了解被提名人职业、学历、职称、详细的工作经历、全部兼职、 有无重大失信等不良记录等情况。被提名人已书面同意出任广州安必 平医药科技股份有限公司第四届董事会独立董事候选人（参见该独立 董事候选人声明）。提名人认为，被提名人具备独立董事任职资格， 与广州安必平医药科技股份有限公司之间不存在任何影响其独立性 的关系，具体声明并承诺如下： 一、被提名人具备上市公司运作的基本知识，熟悉相关法律、行 政法规、规章及其他规范性文件，具有五年以上法律、经济、会计、 财务、管理等履行独立董事职责所必需的工作经验。 被提名人已经参加培训并取得证券交易所认可的相关培训证明 材料。 二、被提名人任职资格符合下列法律、行政法规和部门规章的要 求： （一）《中华人民共和国公司法》等关于董事任职资格的规定； （二）《中华人民共和国公务员法》关于公务员兼任职务的规定 （如适用）； （七）中国人民银行《股份制商业银行独立董事和外部监事制度 指引》等的相关规定（如 ...

证券代码：688393 证券简称：安必平 公告编号：2023-064 广州安必平医药科技股份有限公司 第三届监事会第二十二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、监事会会议召开情况 广州安必平医药科技股份有限公司（以下简称"公司"）第三届监事会第二 十二次会议于 2023 年 12 月 7 日在公司会议室以现场结合通讯方式召开。本次会 议的通知于 2023 年 12 月 4 日以电子邮件、电话等通讯方式送达至公司全体监 事。本次会议由监事会主席彭振武先生召集并主持，会议应参与表决的监事 3 名, 实际参与表决的监事 3 名。本次会议的召集、召开符合相关法律、法规、规则及 《公司章程》的有关规定。 表决结果如下： 提名彭振武先生为公司第四届监事会非职工代表监事候选人，表决结果：同 意 3 票；反对 0 票；弃权 0 票。 提名林上灿先生为公司第四届监事会非职工代表监事候选人，表决结果：同 意 3 票；反对 0 票；弃权 0 票。 1 本议案尚需提交股东大会审议，股东大会将采用累积投票的表决方式对 ...

广州安必平医药科技股份有限公司 独立董事提名人声明与承诺 提名人广州安必平医药科技股份有限公司董事会，现提名吴红日 为广州安必平医药科技股份有限公司第四届董事会独立董事候选人， 并已充分了解被提名人职业、学历、职称、详细的工作经历、全部兼 职、有无重大失信等不良记录等情况。被提名人已书面同意出任广州 安必平医药科技股份有限公司第四届董事会独立董事候选人（参见该 独立董事候选人声明）。提名人认为，被提名人具备独立董事任职资 格，与广州安必平医药科技股份有限公司之间不存在任何影响其独立 性的关系，具体声明并承诺如下： 一、被提名人具备上市公司运作的基本知识，熟悉相关法律、行 政法规、规章及其他规范性文件，具有五年以上法律、经济、会计、 财务、管理等履行独立董事职责所必需的工作经验。 被提名人已经参加培训并取得证券交易所认可的相关培训证明 材料。 二、被提名人任职资格符合下列法律、行政法规和部门规章的要 求： （一）《中华人民共和国公司法》等关于董事任职资格的规定； （二）《中华人民共和国公务员法》关于公务员兼任职务的规定 （如适用）； （三）中国证监会《上市公司独立董事管理办法》、上海证券交 易所自律监管规则以及 ...

广州安必平医药科技股份有限公司 独立董事候选人声明与承诺 本人吴翔，已充分了解并同意由提名人广州安必平医药科技股份 有限公司董事会提名为广州安必平医药科技股份有限公司第四届董 事会独立董事候选人。本人公开声明，本人具备独立董事任职资格， 保证不存在任何影响本人担任广州安必平医药科技股份有限公司独 立董事独立性的关系，具体声明并承诺如下： 一、本人具备上市公司运作的基本知识，熟悉相关法律、行政法 规、部门规章及其他规范性文件，具有五年以上法律、经济会计、财 务、管理等履行独立董事职责所必需的工作经验。 二、本人任职资格符合下列法律、行政法规和部门规章以及公司 规章的要求： （一）《中华人民共和国公司法》等关于董事任职资格的规定； （二）《中华人民共和国公务员法》关于公务员兼任职务的规定 （如适用）； （三）中国证监会《上市公司独立董事管理办法》和上海证券交 易所自律监管规则有关独立董事任职资格和条件的相关规定； （四）中共中央纪委、中共中央组织部《关于规范中管干部辞去 公职或者退（离）休后担任上市公司、基金管理公司独立董事、独立 监事的通知》的规定（如适用）； （五）中共中央组织部《关于进一步规范党政领导干部在 ...

证券代码：688393 证券简称：安必平 公告编号：2023-063 广州安必平医药科技股份有限公司 关于董事会、监事会换届选举的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 广州安必平医药科技股份有限公司（以下简称"公司"）第三届董事会、监 事会任期即将届满，根据《公司法》《上海证券交易所科创板股票上市规则》等 法律、法规以及《公司章程》等相关规定，公司开展董事会、监事会换届选举工 作，现将本次董事会、监事会换届选举情况公告如下： 一、董事会换届选举情况 公司于 2023 年 12 月 7 日召开第三届董事会第二十七次会议，审议通过了 《关于提名第四届董事会非独立董事候选人的议案》、《关于提名第四届董事会独 立董事候选人的议案》，经董事会提名委员会对第四届董事会董事候选人的任职 资格审查，公司董事会同意提名蔡向挺先生、蔡幸伦女士、梁宗胜先生、邓喆锋 先生、陈绍宇先生、王海蛟先生为公司第四届董事会非独立董事候选人；同意提 名彭文平先生、吴翔先生、吴红日先生为公司第四届董事会独立董事候选人。其 中，彭文平先生为会计 ...

广州安必平医药科技股份有限公司 综上，我们一致同意提名前述人员为第四届董事会独立董事候选人，并同 独立董事关于第三届董事会第二十七次会议所审议相关事项的 独立意见 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司独立董 事规则》《上海证券交易所科创板股票上市规则》《广州安必平医药科技股份有限 公司章程》等有关规定，作为广州安必平医药科技股份有限公司（以下简称"公 司"）的独立董事，我们本着对公司及全体股东负责的态度，对公司第三届董事 会第二十七次会议所审议的相关事项，基于独立判断的立场发表意见如下： 一、《关于提名第四届董事会非独立董事候选人的议案》 经审阅蔡向挺先生、蔡幸伦女士、梁宗胜先生、邓喆锋先生、陈绍宇先生、 王海蛟先生的个人简历等相关资料，前述候选人的任职资格符合相关法律、行政 法规、规范性文件对董事任职资格的要求，不存在《公司法》、《公司章程》规定 的不得担任公司董事的情形，未受到中国证券监督管理委员会的政处罚或交易所 惩戒，不存在上海证券交易所认定不适合担任上市公司董事的其他情形。 综上，我们一致同意提名前述人员为第四届董事会非独立董事候选人,并同 意提交公司股东大会审议。 二、《 ...

证券简称：安必平 证券代码：688393 广州安必平医药科技股份有限公司 投资者关系活动记录表 编号：2023-014 □特定对象调研 □分析师会议 □媒体采访 □√业绩说明会 投资者关系 活动类别 □新闻发布会 □路演活动 □√现场参观 □其他 参与单位名称 北京枫瑞资产管理有限公司 吴蕊；国联基金管理有限公司 杜伟；诺安 基金管理有限公司 黄友文；上海人寿保险股份有限公司 方军平； Green Court Kevin Ke；上海景熙资产管理有限公司 张宁；浦银安 盛基金管理有限公司 刘诗瑶；景顺长城基金管理有限公司 张欢；上海 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 投资者可于 2023 年 11 月 22 日(星期三)至 11 月 28 日(星期二)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 （zqswb@gzlbp.com）进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 广州安必平医药科技股份有限公司（以下简称"公司"）已于 2023 年 10 月 31 日发布公司 2023 年第三季度报告，为便于广大投资者更全面深入地了解公 司 2023 年第三季度经营成果、财务状况，公司计划于 2023 年 11 月 29 日上午 9:00-10:00 举行 2023 年第三季度业绩说明会，就投资者关心的问题进行交 流。 一、 说明会类型 本次投资者说明会以网络互动召开，公司将针对 2023 年第三季度的经营成 果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 证券代码：688393 证券简称： ...

[Important Content Reminder](index=1&type=section&id=%E9%87%8D%E8%A6%81%E5%86%85%E5%AE%B9%E6%8F%90%E7%A4%BA) This section outlines the company's formal assurances regarding the accuracy and completeness of its quarterly report [Assurance of Truthfulness by Board, Supervisory Board, and Senior Management](index=1&type=section&id=%E8%91%A3%E4%BA%8B%E4%BC%9A%E3%80%81%E7%9B%91%E4%BA%8B%E4%BC%9A%E5%8F%8A%E9%AB%98%E7%AE%A1%E4%BF%9D%E8%AF%81%E7%9C%9F%E5%AE%9E%E6%80%A7) The board, supervisory board, senior management, and key financial officers collectively guarantee the truthfulness and completeness of the quarterly report and its financial statements - The company's board of directors, supervisory board, and senior management assume legal responsibility for the truthfulness, accuracy, and completeness of the quarterly report content[2](index=2&type=chunk) - The company's principal officer, officer in charge of accounting, and head of the accounting department guarantee the truthfulness, accuracy, and completeness of the financial information[3](index=3&type=chunk) [Key Financial Data](index=1&type=section&id=%E4%B8%80%E3%80%81%E4%B8%BB%E8%A6%81%E8%B4%A2%E5%8A%A1%E6%95%B0%E6%8D%AE) This section presents the company's key financial performance indicators, balance sheet metrics, and non-recurring items, along with explanations for significant changes [Key Accounting Data and Financial Indicators](index=1&type=section&id=%28%E4%B8%80%29%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) The company reported significant Q3 revenue and net profit growth, yet year-to-date cumulative figures declined, alongside a substantial decrease in operating cash flow and increased R&D investment Key Accounting Data and Financial Indicators | Item | Current Reporting Period (Q3 2023) | YoY Change (%) | Year-to-Date (YTD 2023) | YoY Change (%) | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 143,552,528.41 | - | 354,506,458.37 | -5.29 | | Net Profit Attributable to Shareholders of Listed Company | 19,489,757.01 | 130.95 | 37,594,415.51 | -13.86 | | Net Profit Attributable to Shareholders of Listed Company Excluding Non-Recurring Gains and Losses | 21,491,387.99 | 125.66 | 35,456,024.58 | -14.00 | | Net Cash Flow from Operating Activities | Not applicable | Not applicable | 3,210,037.42 | -80.50 | | Basic Earnings Per Share (RMB/share) | 0.21 | 133.33 | 0.40 | -14.89 | | Diluted Earnings Per Share (RMB/share) | 0.20 | 122.22 | 0.40 | -14.89 | | Weighted Average Return on Net Assets (%) | 1.56 | Increased by 0.87 percentage points | 3.02 | Decreased by 0.58 percentage points | | Total R&D Investment | 21,082,857.52 | 26.91 | 54,082,671.78 | 12.93 | | R&D Investment as % of Operating Revenue (%) | 14.69 | Increased by 2.09 percentage points | 15.26 | Increased by 2.47 percentage points | Key Balance Sheet Indicators | Indicator | End of Current Reporting Period (2023.09.30) | End of Prior Year (2022.12.31) | Change from Prior Year-End (%) | | :--- | :--- | :--- | :--- | | Total Assets | 1,381,770,194.59 | 1,392,783,829.88 | -0.79 | | Total Equity Attributable to Shareholders of Listed Company | 1,264,081,082.24 | 1,228,605,285.24 | 2.89 | [Non-Recurring Gains and Losses and Amounts](index=2&type=section&id=%28%E4%BA%8C%29%E9%9D%9E%E7%BB%8F%E5%B8%B8%E6%80%A7%E6%8D%9F%E7%9B%8A%E9%A1%B9%E7%9B%AE%E5%92%8C%E9%87%91%E9%A2%9D) The current period's total non-recurring gains and losses were negative due to net non-operating expenses, while year-to-date figures were positive, driven by government subsidies and entrusted investment income Non-Recurring Gains and Losses and Amounts | Item | Amount for Current Reporting Period (Q3 2023) | Amount Year-to-Date (YTD 2023) | | :--- | :--- | :--- | | Gains/Losses from Disposal of Non-Current Assets | 1,003.88 | -70,137.79 | | Government Subsidies Included in Current Profit/Loss | 220,368.28 | 2,815,782.56 | | Gains/Losses from Entrusted Investment or Asset Management | -149,576.43 | 3,492,706.98 | | Other Non-Operating Income and Expenses | -2,453,706.86 | -3,953,625.74 | | Other Profit/Loss Items Meeting the Definition of Non-Recurring Gains/Losses | - | 161,982.08 | | Less: Income Tax Impact | -389,345.00 | 205,298.39 | | Minority Interest Impact (After Tax) | 9,064.85 | 103,018.77 | | Total | -2,001,630.98 | 2,138,390.93 | [Changes in Key Accounting Data, Financial Indicators and Reasons](index=3&type=section&id=%28%E4%B8%89%29%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E3%80%81%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87%E5%8F%91%E7%94%9F%E5%8F%98%E5%8A%A8%E7%9A%84%E6%83%85%E5%86%B5%E3%80%81%E5%8E%9F%E5%9B%A0) Current period net profit and non-recurring net profit significantly increased due to higher revenue and lower expenses, while year-to-date operating cash flow declined sharply from reduced sales collections and increased employee compensation - Net profit attributable to shareholders and net profit attributable to shareholders excluding non-recurring gains and losses for the current period increased by **130.95%** and **125.66%** respectively, primarily due to increased revenue and reduced period expenses[9](index=9&type=chunk) - Net cash flow from operating activities decreased by **80.50%** year-to-date, mainly due to lower sales collections and increased employee compensation compared to the prior year[9](index=9&type=chunk) - Basic earnings per share increased by **133.33%** for the current period, primarily driven by increased profit[9](index=9&type=chunk) [Shareholder Information](index=3&type=section&id=%E4%BA%8C%E3%80%81%E8%82%A1%E4%B8%9C%E4%BF%A1%E6%81%AF) This section provides details on the total number of shareholders and the top ten shareholders' holdings, including information on controlling shareholders and related parties [Total Number of Common Shareholders, Preferred Shareholders with Restored Voting Rights, and Top Ten Shareholders' Holdings](index=3&type=section&id=%28%E4%B8%80%29%E6%99%AE%E9%80%9A%E8%82%A1%E8%82%A1%E4%B8%9C%E6%80%BB%E6%95%B0%E5%92%8C%E8%A1%A8%E5%86%B3%E6%9D%83%E6%81%A2%E5%A4%8D%E7%9A%84%E4%BC%98%E5%85%88%E8%82%A1%E8%82%A1%E4%B8%9C%E6%95%B0%E9%87%8F%E5%8F%8A%E5%89%8D%E5%8D%81%E5%90%8D%E8%82%A1%E4%B8%9C%E6%8C%81%E8%82%A1%E6%83%85%E5%86%B5%E8%A1%A8) As of the reporting period end, the company had **8,263** common shareholders, with high concentration among the top ten, including a significant combined stake held by controlling shareholder Cai Xiangting and his affiliates - The total number of common shareholders at the end of the reporting period was **8,263**[10](index=10&type=chunk) Top 10 Shareholders' Holdings | Shareholder Name | Shareholder Nature | Number of Shares Held (shares) | Shareholding Percentage (%) | | :--- | :--- | :--- | :--- | | Cai Xiangting | Domestic Natural Person | 19,817,000 | 21.18 | | Guangzhou Kaiduo Investment Consulting Center (Limited Partnership) | Other | 12,951,400 | 13.84 | | Zhuji Gaotejia Ruian Investment Partnership (Limited Partnership) | Other | 5,628,313 | 6.02 | | Xiamen Qianjing Enterprise Management Partnership (Limited Partnership) | Other | 5,358,418 | 5.73 | | Guangzhou Da'an Gene Technology Co., Ltd. | Domestic Non-State-Owned Legal Person | 3,486,000 | 3.73 | | Chongqing Gaotejia Ruian Equity Investment Fund Partnership (Limited Partnership) | Other | 2,407,600 | 2.57 | | Hangzhou Gaotejia Ruihai Investment Partnership (Limited Partnership) | Other | 1,480,679 | 1.58 | | Hangzhou Ruihong Investment Partnership (Limited Partnership) | Other | 722,467 | 0.77 | | Pan Weihua | Domestic Natural Person | 578,277 | 0.62 | | Feng Xiaodong | Domestic Natural Person | 513,888 | 0.55 | - Controlling shareholder Cai Xiangting is the executive partner of Guangzhou Kaiduo Investment Consulting Center (Limited Partnership), holding **69.64%** of its partnership interest[11](index=11&type=chunk) - Zhuji Gaotejia Ruian Investment Partnership, Chongqing Gaotejia Ruian Equity Investment Fund Partnership, Hangzhou Gaotejia Ruihai Investment Partnership, and Hangzhou Ruihong Investment Partnership are parties acting in concert[11](index=11&type=chunk) [Other Reminders](index=5&type=section&id=%E4%B8%89%E3%80%81%E5%85%B6%E4%BB%96%E6%8F%90%E9%86%92%E4%BA%8B%E9%A1%B9) This section addresses any other significant operational information requiring investor attention during the reporting period [Other Important Information Regarding the Company's Operating Performance During the Reporting Period Requiring Investor Attention](index=5&type=section&id=%E9%9C%80%E6%8F%90%E9%86%92%E6%8A%95%E8%B5%84%E8%80%85%E5%85%B3%E6%B3%A8%E7%9A%84%E5%85%B3%E4%BA%8E%E5%85%AC%E5%8F%B8%E6%8A%A5%E5%91%8A%E6%9C%9F%E7%BB%8F%E8%90%A5%E6%83%85%E5%86%B5%E7%9A%84%E5%85%B6%E4%BB%96%E9%87%8D%E8%A6%81%E4%BF%A1%E6%81%AF) The company has no other significant operating information requiring special investor attention during the reporting period - The company has no other important operating information requiring investor attention during the reporting period[12](index=12&type=chunk) [Quarterly Financial Statements](index=5&type=section&id=%E5%9B%9B%E3%80%81%E5%AD%A3%E5%BA%A6%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8) This section presents the company's unaudited consolidated financial statements, including the balance sheet, income statement, and cash flow statement [Type of Audit Opinion](index=5&type=section&id=%28%E4%B8%80%29%E5%AE%A1%E8%AE%A1%E6%84%8F%E8%A7%81%E7%B1%BB%E5%9E%8B) The financial statements for the current quarter are unaudited - The financial statements for the current quarter are unaudited[12](index=12&type=chunk) [Financial Statements](index=5&type=section&id=%28%E4%BA%8C%29%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8) This section presents the company's unaudited consolidated balance sheet, income statement, and cash flow statement as of September 30, 2023, and for the nine months then ended [Consolidated Balance Sheet](index=5&type=section&id=%E5%90%88%E5%B9%B6%E8%B5%84%E4%BA%A7%E8%B4%9F%E5%80%BA%E8%A1%A8) As of September 30, 2023, total assets slightly decreased, driven by lower current assets and higher non-current assets, while total liabilities decreased and owners' equity slightly grew Consolidated Balance Sheet Key Item Changes (2023.09.30 vs 2022.12.31) | Item | September 30, 2023 (RMB) | December 31, 2022 (RMB) | Change (%) | | :--- | :--- | :--- | :--- | | Cash and Cash Equivalents | 64,396,563.04 | 90,910,709.73 | -29.17 | | Financial Assets Held for Trading | 61,204,917.06 | 175,536,506.82 | -65.17 | | Accounts Receivable | 250,622,859.34 | 236,164,593.91 | 6.12 | | Inventories | 75,920,754.68 | 63,073,696.31 | 20.37 | | Non-Current Assets Due Within One Year | 72,853,774.43 | 0 | Newly Added | | Total Current Assets | 550,482,342.58 | 595,076,395.73 | -7.50 | | Other Non-Current Financial Assets | 173,238,842.50 | 147,449,916.08 | 17.49 | | Development Expenditures | 10,941,294.39 | 1,463,347.82 | 647.75 | | Total Non-Current Assets | 831,287,852.01 | 797,707,434.15 | 4.21 | | Total Assets | 1,381,770,194.59 | 1,392,783,829.88 | -0.79 | | Total Current Liabilities | 90,505,774.12 | 114,264,335.81 | -20.79 | | Total Liabilities | 142,721,204.12 | 170,447,006.45 | -16.38 | | Total Equity Attributable to Parent Company Shareholders | 1,264,081,082.24 | 1,228,605,285.24 | 2.89 | - Cash and cash equivalents and financial assets held for trading significantly decreased, while accounts receivable and inventories increased[13](index=13&type=chunk) - Development expenditures significantly increased, reflecting the company's increased investment in research and development[14](index=14&type=chunk) [Consolidated Income Statement](index=7&type=section&id=%E5%90%88%E5%B9%B6%E5%88%A9%E6%B6%A6%E8%A1%A8) For the first three quarters of 2023, total operating revenue, operating profit, and net profit all declined year-on-year, while sales and R&D expenses increased as a percentage of revenue Consolidated Income Statement Key Item Changes (Q1-Q3 2023 vs Q1-Q3 2022) | Item | Q1-Q3 2023 (Jan-Sep) (RMB) | Q1-Q3 2022 (Jan-Sep) (RMB) | YoY Change (%) | | :--- | :--- | :--- | :--- | | Total Operating Revenue | 354,506,458.37 | 374,325,569.60 | -5.29 | | Operating Cost | 109,012,703.38 | 104,857,804.61 | 3.96 | | Selling Expenses | 125,589,751.86 | 132,682,257.48 | -5.35 | | Administrative Expenses | 58,819,729.69 | 53,795,656.72 | 9.34 | | R&D Expenses | 44,604,725.21 | 47,111,809.08 | -5.32 | | Operating Profit | 24,392,685.66 | 39,189,506.75 | -37.89 | | Total Profit | 20,439,059.92 | 38,591,651.76 | -47.03 | | Net Profit | 18,830,785.55 | 34,030,155.66 | -44.66 | | Net Profit Attributable to Parent Company Shareholders | 37,594,415.51 | 43,644,589.05 | -13.86 | | Basic Earnings Per Share (RMB/share) | 0.40 | 0.47 | -14.89 | - Total operating revenue decreased by **5.29%** year-on-year, leading to significant declines in operating profit, total profit, and net profit[19](index=19&type=chunk)[20](index=20&type=chunk) - Minority interest income/loss was negative and the loss expanded, impacting net profit attributable to parent company shareholders[20](index=20&type=chunk) [Consolidated Cash Flow Statement](index=10&type=section&id=%E5%90%88%E5%B9%B6%E7%8E%B0%E9%87%91%E6%B5%81%E9%87%8F%E8%A1%A8) For Q1-Q3 2023, net operating cash flow significantly decreased, while net investing cash outflow narrowed, net financing cash outflow slightly increased, and period-end cash and cash equivalents declined year-on-year Consolidated Cash Flow Statement Key Item Changes (Q1-Q3 2023 vs Q1-Q3 2022) | Item | Q1-Q3 2023 (Jan-Sep) (RMB) | Q1-Q3 2022 (Jan-Sep) (RMB) | YoY Change (%) | | :--- | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 3,210,037.42 | 16,462,893.85 | -80.50 | | Net Cash Flow from Investing Activities | -15,856,588.49 | -116,031,451.65 | 86.35 (Loss narrowed) | | Net Cash Flow from Financing Activities | -15,888,900.14 | -16,201,889.92 | 1.93 (Loss narrowed) | | Net Increase in Cash and Cash Equivalents | -28,614,146.69 | -115,580,870.56 | 75.25 (Loss narrowed) | | Cash and Cash Equivalents at Period End | 61,388,563.04 | 100,885,273.04 | -39.15 | - Decreased cash received from sales of goods and services, coupled with increased employee compensation, were the primary reasons for the significant decline in net cash flow from operating activities[23](index=23&type=chunk)[24](index=24&type=chunk) - Net cash outflow from investing activities significantly narrowed, mainly due to a substantial reduction in cash paid for the acquisition of fixed assets, intangible assets, and other long-term assets, as well as cash paid for investments[24](index=24&type=chunk) [Adjustments to Financial Statements at the Beginning of the First Year of Application of New Accounting Standards or Interpretations from 2023](index=12&type=section&id=2023%20%E5%B9%B4%E8%B5%B7%E9%A6%96%E6%AC%A1%E6%89%A7%E8%A1%8C%E6%96%B0%E4%BC%9A%E8%AE%A1%E5%87%86%E5%88%99%E6%88%96%E5%87%86%E5%88%99%E8%A7%A3%E9%87%8A%E7%AD%89%E6%B6%89%E5%8F%8A%E8%B0%83%E6%95%B4%E9%A6%96%E6%AC%A1%E6%89%A7%E8%A1%8C%E5%BD%93%E5%B9%B4%E5%B9%B4%E5%88%9D%E7%9A%84%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8) The company did not adopt new accounting standards or interpretations from 2023 that required adjustments to the financial statements at the beginning of the first year of application - The company did not adopt new accounting standards or interpretations from 2023 that required adjustments to the financial statements at the beginning of the first year of application[25](index=25&type=chunk)

证券代码：688393 证券简称：安必平 公告编号：2023-060 本公司监事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 广州安必平医药科技股份有限公司（以下简称"公司"）第三届监事会第二 十一次会议于 2023 年 10 月 30 日在公司会议室以现场结合通讯方式召开。本次 会议的通知于 2023 年 10 月 27 日以电子邮件、电话等通讯方式送达至公司全体 监事。本次会议由监事会主席彭振武先生召集并主持，会议应参与表决的监事 3 名,实际参与表决的监事 3 名。本次会议的召集、召开符合相关法律、法规、规 则及《公司章程》的有关规定。 二、监事会会议审议情况 经与会监事投票表决，审议通过了如下议案： （一）审议通过了《关于公司 2023 年第三季度报告的议案》 监事对 2023 年第三季度报告中关键指标等进行了审核，一致认为，公司 2023 年第三季度报告的编制符合法律、法规、规范性文件的规定，报告的内容真实、 准确、完整地反映了公司的实际情况。 表决结果：同意 3 票；反对 0 票；弃权 0 票。 ...